<DOC>
	<DOCNO>NCT00477750</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , melphalan , prednisone , lenalidomide , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose melphalan lenalidomide give together prednisone see well work treat patient newly diagnose multiple myeloma .</brief_summary>
	<brief_title>Melphalan , Prednisone , Lenalidomide Treating Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose melphalan lenalidomide combination prednisone patient newly diagnose multiple myeloma . - Determine response rate patient treat regimen . Secondary - Determine toxicity regimen patient . OUTLINE : This dose-escalation study melphalan lenalidomide follow phase II study . - Phase I : Patients receive oral melphalan oral prednisone daily day 1-4 . Patients also receive oral lenalidomide daily day 1-21 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos melphalan lenalidomide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . * Phase II : Patients receive oral melphalan oral lenalidomide phase I MTD . Patients also receive oral prednisone phase I . Treatment repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma Newly diagnose disease Requires treatment , judgment treat physician Not candidate ( patient decline ) autologous stem cell transplantation Meets 1 follow criterion : Measurable disease , define follow : Serum monoclonal protein ≥ 1 g/dL Urine protein monoclonal light chain ≥ 200 mg/24 hour electrophoresis Measurable serum free light chain ≥ 10 mg/dL , kappa lambda , AND κ/λ ratio abnormal ( serum urine measurable define ) Evaluable disease , define monoclonal bone marrow plasmacytosis ≥ 30 % PATIENT CHARACTERISTICS : ECOG performance status 03 Life expectancy &gt; 3 month ANC ≥ 1,500/mm³ Bilirubin ≤ 2.0 mg/dL Alkaline phosphatase ≤ 3 time upper limit normal ( ULN ) AST ≤ 3 time ULN Creatinine ≤ 3.0 mg/dL Platelet count ≥ 100,000/mm³ Not pregnant nursing Negative pregnancy test Fertile patient must use 2 effective method contraception , include ≥ 1 highly effective method , ≥ 4 week study treatment No uncontrolled infection No peripheral neuropathy ≥ grade 2 No serious medical condition , laboratory abnormality , psychiatric illness would preclude study compliance No active malignancy except nonmelanoma skin cancer carcinoma situ Prior malignancy allow treated curative intent free disease period appropriate cancer No know hypersensitivity thalidomide No known HIV positivity No infectious hepatitis A , B C No history deep vein thrombosis medical condition require use warfarin Able take daily prophylactic acetylsalicylic acid ( 81 325 mg ) PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior radiotherapy treatment multiple myeloma No prior lenalidomide No concurrent anticancer agent treatments No concurrent steroid except prednisone ≤ 20 mg/day ( equivalent ) concurrent illness adrenal replacement therapy No concurrent investigational therapy agent treatment multiple myeloma No concurrent warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>